Fragmin (dalteparin sodium) / Pfizer, Eisai - LARVOL DELTA

Cerebral venous thrombosis in pregnancy. (PubMed, BMJ Case Rep) - "Treatment with a two times per day dosing regimen of dalteparin was commenced until elective caesarean section at 37 weeks gestation, after which treatment was changed to warfarin therapy for a further 6 months. Her follow-up recovery was good; she remains asymptomatic. This case highlights difficulties in detecting CVT and treatment of CVT in the third trimester of pregnancy."

Journal • Cardiovascular • Diabetes • Endocrine Disorders • Gestational Diabetes • Hematological Disorders • Metabolic Disorders • Obstetrics • Pain • Thrombosis • Venous Thromboembolism

ANTICOAGULANT - ASSOCIATED ACUTE KIDNEY INJURY: A PHARMACOVIGILANCE ANALYSIS BASED ON FDA ADVERSE EVENT REPORTING SYSTEM (ISN-WCN 2026) - "A).Warfarin had stable low reports, while newer oral anticoagulants (NOACs) showed dramatic trends: Apixaban peaked over 20,000 around 2021, Rivaroxaban near 20,000 in 2015, Dabigatran over 11,000 in 2012. Drugs like Argatroban, Bivalirudin, and Dalteparin had consistently low reports (Fig...Results show heterogeneity in renal ADRs; Fondaparinux and Apixaban signal specific toxicities. Findings can guide pharmacovigilance and clinical decisions for renal risk patients."

Adverse events • Acute Kidney Injury • Nephrology • Renal Disease • ROR1

Impact of dalteparin sodium and luteal phase support on serum markers, interleukins, and pregnancy outcomes in patients with in vitro fertilisation failure. (PubMed, J Med Biochem) - "The combination of LPS and DS appears to be a safe and effective strategy for improving pregnancy outcomes and QOL in patients with repeated IVF failure. This combined treatment may exert its beneficial effects by modulating key serum markers and interleukins, such as CA-125 and IL-6, involved in implantation and pregnancy maintenance."

Journal • Preclinical • Gynecology • Infertility • Sexual Disorders • IL6

A Service Evaluation of Anti-Xa Measurements in Patients with Kidney Impairment in A Tertiary Centre (UKKW 2026) - "In this report, trough anti Xa measurement of dalteparin independently predicts bleeding in patients with renal impairment. Patients receiving dalteparin for longer durations, particularly beyond 19 days, may be at increased risk of accumulation-related bleeding. Further prospective, larger studies are warranted to validate these results before it can be universally recommended in clinical practice."

Clinical • Cardiovascular • Hematological Disorders • Renal Disease • Thrombosis

The Intensive Care Platform Trial (INCEPT) (clinicaltrialsregister.eu) - P4 | N=40000 | Recruiting | Sponsor: Rigshospitalet

New P4 trial • Critical care

APHP240923: PALETTE - Trial for personalisation of sepsis treatment in children and adults (clinicaltrialsregister.eu) - P1/2 | N=2000 | Not yet recruiting | Sponsor: Assistance Publique Hopitaux De Paris

New P1/2 trial • Pan tumor • Infectious Disease • Septic Shock

A Service Evaluation of Anti-Xa Measurements in Patients with Kidney Impairment in A Tertiary Centre. (PubMed, Nephron) - "In this report, trough anti-Xa measurement of dalteparin is independently associated with bleeding in patients with CKD. Further prospective, larger studies are warranted to validate these results before it can be universally recommended in clinical practice."

Journal • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease • Thrombosis

Rivaroxaban in comparison with low molecular weight heparin for the treatment of cancer-associated thrombosis: a systematic review and meta-analysis (PubMed, Angiol Sosud Khir) - "In patients with cancer-associated thrombosis, the use of rivaroxaban in comparison with LMWH is associated with a reduced risk of VTE recurrence without an increase in the risk of major bleeding and does not affect all-cause mortality."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Oncology • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Double pylorus in an elderly female patient: a case report. (PubMed, J Med Case Rep) - "Double pylorus is a rare but clinically relevant condition that may first be detected when complications such as gastrointestinal bleeding occur. Reported associations with H. pylori infection and nonsteroidal anti-inflammatory drug exposure represent observational trends rather than established causal relationships, as the evidence remains heterogeneous and limited. The condition likely develops in the setting of multifactorial impairment of gastroduodenal mucosal integrity, particularly in older or medically vulnerable individuals."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Pain • Peptic Ulcer

Impact of postoperative weight loss on anticoagulant dosing after major lower limb amputation. (PubMed, Ann R Coll Surg Engl) - "Major amputation is associated with clinically relevant postoperative weight loss, yet anticoagulant dose adjustments were uncommon. Routine postoperative weight monitoring and prompt review of weight-based therapy are recommended to improve dosing accuracy and reduce potential anticoagulation risk."

Journal

Spontaneous inferior epigastric artery hemorrhage in a COVID-19 patient with membranous nephropathy on anticoagulant therapy: a Case Report. (PubMed, Front Med (Lausanne)) - "Despite prophylactic anticoagulation with dalteparin, her respiratory status deteriorated, requiring intensive care...It underscores the need for individualized anticoagulation strategies, pharmacodynamic monitoring, and multidisciplinary decision-making to mitigate risks in this high-risk population. The interplay of COVID-19-induced coagulopathy, renal impairment, and immunosuppressive therapy amplifies both thrombotic and hemorrhagic tendencies, necessitating extreme vigilance in clinical management."

Journal • Acute Respiratory Distress Syndrome • Critical care • Glomerulonephritis • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases

Discovery of a Piperazine-Based Quaternary Ammonium Macrocycle as a Universal Reversal Agent for Heparin Anticoagulants. (PubMed, J Med Chem) - "Here, we report that a piperazine-derived tetracationic macrocycle can efficiently neutralize both UFH and LMWHs, including dalteparin, enoxaparin, and nadroparin. In vitro and in vivo assays reveal that the compound outperforms protamine, exhibiting significantly improved neutralization activity, a broad therapeutic window for all heparins, and high biocompatibility, which is confirmed by its very low coagulation and hemolysis effect, as well as a high therapeutic index (20.5), defined as the ratio of the maximum tolerated dose to the effective therapeutic dose. Molecular dynamics simulations indicate that binding may occur through interlocked threading and direct contact patterns, which are stabilized by intermolecular hydrogen bonding and ion-pair electrostatic attraction."

Journal • Hematological Disorders

Prophylaxis for venous thromboembolism in traumatic brain injury: protocol for a randomised controlled trial. (PubMed, BMJ Open) - P3 | "The study design is a Bayesian adaptive RCT comparing early (within three calendar days of injury) versus delayed (after study Day 7) VTE prophylaxis with the LMWH, dalteparin...The results of this trial will help guide clinicians aiming to balance the risks and benefits of early anticoagulant prophylaxis after TBI and will inform guideline development. NCT03559114."

Clinical protocol • Journal • Cardiovascular • CNS Disorders • Critical care • Vascular Neurology • Venous Thromboembolism

The Necessity to Provide an Informed Choice Regarding Venous Thromboembolism Prophylaxis: A Single-Centre Study Observing Clinician Adherence and Opinions on Venous Thromboembolism Prophylaxis. (PubMed, Cureus) - "These are often done via nonpharmacological methods, such as anti-embolic (TED™) stockings, or with pharmacological methods, such as low molecular weight heparin (LMWH), which consists of medications such as dalteparin...Fondaparinux sodium, a fully synthetic alternative, offers a non-animal-derived option, yet its use remains limited...This demonstrates a clear health inequality. Educational initiatives and institutional protocols are recommended to promote patient-centred care and ensure ethical prescribing consistent with individual values."

Journal • Cardiovascular • Venous Thromboembolism

The win ratio for evaluating edoxaban versus dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE cancer trial. (PubMed, J Thromb Haemost) - "We observed no significant difference between edoxaban and dalteparin for the treatment of cancer-associated VTE when using the win-ratio approach with a hierarchy of 10 prioritized outcomes."

Journal • Cardiovascular • Hematological Disorders • Oncology • Venous Thromboembolism

MAGNOLIA: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (clinicaltrials.gov) - P3 | N=417 | Active, not recruiting | Sponsor: Anthos Therapeutics, Inc. | Recruiting ➔ Active, not recruiting | N=1020 ➔ 417

Enrollment change • Enrollment closed • Cardiovascular • Genito-urinary Cancer • Oncology • Respiratory Diseases • Solid Tumor • Venous Thromboembolism

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Tzu-Fei Wang | Trial completion date: Mar 2025 ➔ Jan 2027 | Trial primary completion date: Oct 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Oncology • Thrombocytopenia • Thrombosis

CRITICALKidsTP: Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP) (clinicaltrials.gov) - P3 | N=802 | Not yet recruiting | Sponsor: Johns Hopkins All Children's Hospital | Trial completion date: Jun 2030 ➔ Jun 2031 | Trial primary completion date: Jun 2029 ➔ Jun 2030

Trial completion date • Trial primary completion date • Cardiovascular • Venous Thromboembolism

Thrombosis and outcomes in hematologic neoplasia: Experience from a specialized cancer center in a developing country (ASH 2025) - "Inclusion criteria were adult patients (≥18 years) with a diagnosis of a hematologicmalignancy who presented a thrombotic episode after diagnosis and received anticoagulation therapybased on the institutional protocol (Dalteparin 200 IU/kg during the first month, followed by 150 IU/kgthereafter)...In this study, obesity and female gender were identified as independent predictors of recurrentthrombosis despite guideline-based LMWH therapy. Younger age was associated with a slightly higherrisk of bleeding events. No clinical characteristic was significantly associated with death followingthrombotic episodes, though statistical power may have been limited due to small sample size resultingfrom loss of follow-up."

Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Obesity • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Undiagnosed patent foramen ovale with bi-atrial thrombus in transit: A case of pulmonary embolism and refractory hypoxia (ASH 2025) - "She was started on weight-based low-molecular-weight heparin(dalteparin) without dose capping.Despite therapeutic anticoagulation, the patient remained persistently hypoxic throughout herhospitalization, requiring 4 L/min of supplemental oxygen via nasal cannula to maintain oxygensaturation above 92%...The patient's postoperative course was complicated by infective endocarditis involvingher pulmonic valve; however, she recovered and was transitioned to warfarin for ongoinganticoagulation...In these cases, surgical thrombectomy with PFO closure tends to lead to better outcomescompared to anticoagulation or thrombolysis alone by decreasing the risk of systemic embolization anddeath. In cases of PE accompanied by persistent hypoxia or clinical deterioration, a thrombus in transitshould be considered early in the diagnostic process to guide timely, definitive treatment."

Clinical • Cardiovascular • Gastroenterology • Genetic Disorders • Hematological Disorders • Hypotension • Obesity • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Venous Thromboembolism

BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report. (PubMed, Br J Dermatol) - "The efficacy of ritlecitinib, an oral Janus kinase 3/TEC family inhibitor, has been demonstrated in the Allegro clinical trials...The US Food and Drug Administration issued black box warnings, citing increased risks of major adverse cardiovascular events, malignancies, venous thromboembolism (VTE) and mortality based on data from tofacitinib, baricitinib and upadacitinib in rheumatoid arthritis...The patient received intravenous broad-spectrum antibiotics for sepsis of unknown origin, hydrocortisone and vasopressor support for hypotension. She was anticoagulated with dalteparin and transitioned to apixaban as per respiratory advice for unprovoked pulmonary emboli...This case highlights a probable severe adverse event associated with ritlecitinib therapy, including pulmonary emboli and infection of unidentified source, associated with new-onset atrial fibrillation and acute kidney injury in a patient without known risk factors for VTE. Ongoing pharmacovigilance is..."

Journal • Acute Kidney Injury • Alopecia • Atrial Fibrillation • Cardiovascular • Dermatology • Endocrine Disorders • Hematological Disorders • Herpes Zoster • Hypotension • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Musculoskeletal Pain • Nephrology • Novel Coronavirus Disease • Oncology • Pain • Pneumococcal Infections • Pruritus • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Septic Shock • Varicella Zoster • Venous Thromboembolism • CRP • JAK3

Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE. (PubMed, Res Pract Thromb Haemost) - "In this large, observational study, enoxaparin, particularly in twice-daily regimens, was associated with significantly increased risks of bleeding and mortality compared to tinzaparin/dalteparin. These findings may help refine LMWH selection and dosing strategies in patients with cancer-associated VTE and warrant further investigation in prospective studies."

Journal • Real-world evidence • Cardiovascular • Oncology • Venous Thromboembolism

Nucleotide-Dependent Actin Conformations Revealed by Multiscale Enhanced Sampling. (PubMed, Biophys J) - "As a simple model of F-actin, we adopted recent high-resolution crystal structures of actin complexed with actin-binding protein, fragmin domain-1...These results explain the directional nature of filament formation that ATP-bound G-actin preferentially associates with the barbed end, while ADP-bound F-actin dissociates from the pointed end. Atom contact analysis clarified that the γ-phosphate in ATP binding to actin subdomain 1 contributes to nucleotide-dependent actin flexibility."

Journal

Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome. (PubMed, Kidney Med) - P1/2 | "Guidelines recommend prophylactic anticoagulation with warfarin or low molecular weight heparin...Patients with NS received weight-adjusted dalteparin for at least 4 days, followed by a washout period of ≥ 24 hours, before starting apixaban 5 mg twice daily for a minimum of 4 days...This supports apixaban as a viable alternative for thromboprophylaxis in NS. ClinicalTrials.gov: NCT04850378; EudraCT: 2019-001212-29."

Journal • Cardiovascular • Glomerulonephritis • Nephrology • Renal Disease • Venous Thromboembolism

High intensity interval training and dalteparin attenuate doxorubicin induced cardiac damage and FoxO4 protein level in rats. (PubMed, Sci Rep) - "The HIIT program and DAL treatment significantly reduced tissue damage, enhanced cardiac function, and decreased FoxO4 expression in rats. These findings suggest that these strategies may help mitigate DOX-related cardiac injury."

Journal • Preclinical • Cardiovascular • Fibrosis • Immunology • Oncology